Impact BioMedical
8 hedge funds and large institutions have $76.1K invested in Impact BioMedical in 2024 Q4 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, 1 reducing their positions, and 4 closing their positions.
84% more capital inflows, than outflows
Capital inflows: $109K | Capital outflows: $59.4K
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
33% more funds holding
Funds holding: 6 → 8 (+2)
0.2% more ownership
Funds ownership: 0.26% → 0.46% (+0.2%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$43.1K |
| 2 |
FNY Investment Advisers
New York
|
+$26.1K |
| 3 |
State Street
Boston,
Massachusetts
|
+$23.2K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$8.82K |
| 5 |
Tower Research Capital (TRC)
New York
|
+$7.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$26.7K |
| 2 |
HRT Financial
New York
|
-$25K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$5.37K |
| 4 |
Barclays
London,
United Kingdom
|
-$2.24K |
| 5 |
Morgan Stanley
New York
|
-$116 |
IBO Hedge Fund Activity: Q4 2024 in Review
8 of the 7,624 institutional investors tracked by Wall St. Rank reported a position in Impact BioMedical (IBO) for Q4 2024, worth a combined $76.1K — up 28% from $59.3K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new IBO positions and 4 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $43.1K. The largest seller was Jane Street, exiting entirely with an estimated $26.7K sold.
- 8 institutional investors held Impact BioMedical (IBO) as of Q4 2024, up from 6 in Q3 2024.
- Funds reported $76.1K of Impact BioMedical stock for Q4 2024, up 28% quarter-over-quarter.
- 6 funds opened new Impact BioMedical positions in Q4 2024 and 4 closed out, a net change of +2 holders.
- The largest Impact BioMedical buyer in Q4 2024 was Geode Capital Management, an estimated $43.1K added.
- The largest Impact BioMedical seller in Q4 2024 was Jane Street, an estimated $26.7K sold.
Based on aggregated 13F filings for Q4 2024.